Medifast's Third Quarter 2024 Financial Results
BALTIMORE - Medifast (NYSE: MED), recognized for its innovative health and wellness solutions, recently announced its financial results for the third quarter ending September 30, 2024, revealing significant changes in its performance metrics and strategic focus.
Key Financial Highlights for Q3 2024
During the third quarter, Medifast reported:
- Revenue of $140.2 million at a rate of $4,672 per active earning coach.
- A total of 30,000 independent active earning OPTAVIA coaches.
- Net income of $1.1 million, with a non-GAAP adjusted net income of $3.9 million.
- An income of $0.10 per diluted share, with non-GAAP adjusted earnings per share of $0.35.
- Cash, cash equivalents, and investment securities totaling $170.0 million, with no existing debt.
Leadership Insights
Dan Chard, the Chairman & CEO of Medifast, commented on their mission to revolutionize the weight loss industry. “Medical innovation has shaped our approach at Medifast. We are committed to creating tailored health and wellness solutions to cater to diverse customer needs, ensuring everyone has access to the support they require,” Chard stated.
Chard emphasized their dedication to providing comprehensive support to medication users through innovative collaborations with clinical partners, showcasing the importance of ensuring that customers receive personalized solutions.
Q3 Performance Analysis
Medifast's revenue decreased by 40.6% compared to last year’s Q3 revenue of $235.9 million. This decline resulted from a decrease in active OPTAVIA coaches and reduced productivity among coaches, reflecting the ongoing challenges in customer acquisition. The number of active earning OPTAVIA coaches dropped to 30,000 from 47,100 in the same period last year.
Gross profit reflected a similar trend, decreasing by 40.4% to $105.7 million compared to $177.4 million in Q3 of 2023. Despite this dip, the gross profit margin slightly improved to 75.4%, compared to 75.2% in the previous year.
Expense Management and Profitability
Medifast managed to reduce its selling, general, and administrative expenses (“SG&A”) by 31.8% to $103.6 million, down from $151.9 million a year prior. This management initiative involved decreased compensation expenses for OPTAVIA coaches due to lower earnings capacity.
The company's income from operations also saw a dramatic decrease of 91.7%, amounting to $2.1 million compared to $25.5 million in the same quarter last year, translating to a 1.5% income from operations as a portion of revenue.
Moreover, the effective tax rate rose to 28.5%, marking a significant increase due to diminishing tax benefits from inventory donations when compared with previous periods.
Capital Allocation Strategy
Medifast maintained a strong balance sheet with $170 million in available cash assets and no debt as of September 30, 2024. As part of its current strategy, the company decided to cancel its $225 million credit facility agreement as part of the 'Fuel for the Future' initiative, anticipating annual savings of around $500,000 in commitment fees.
Looking Ahead: Q4 Expectations
For the upcoming quarter, Medifast forecasts that revenue will lie between $100 million and $120 million, with a projected diluted loss per share ranging from $0.10 to $0.65, not accounting for potential gains or losses associated with market fluctuations of its LifeMD investment.
About Medifast
Medifast (NYSE: MED) champions a holistic approach toward weight management and wellness through its signature OPTAVIA program. Focused on transformative lifestyle changes, the company emphasizes support through independent coaching and a wide array of scientifically formulated products. Committed to its mission, Medifast continues to advocate for sustainable, long-term health transformations.
Frequently Asked Questions
What were Medifast's revenues for Q3 2024?
Medifast reported revenues of $140.2 million for the third quarter of 2024.
How many active OPTAVIA coaches does Medifast have?
As of Q3 2024, Medifast has approximately 30,000 active OPTAVIA coaches.
What was the net income for Medifast in Q3 2024?
The company's net income for the third quarter of 2024 was $1.1 million.
What is the company's outlook for Q4 2024?
Medifast anticipates that revenues for Q4 2024 will range between $100 million and $120 million.
How has Medifast adjusted its expense management strategy?
The company reduced SG&A expenses significantly by managing compensation and event-related costs in response to decreased operational capacity.
